Inhaled treprostinil shows promise for exercise capacity in PAH-ILD patients
NCT ID NCT05564637
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how an inhaled drug called treprostinil helps patients with pulmonary hypertension caused by interstitial lung disease. Researchers measured heart function and breathing efficiency during exercise after 3 months of treatment. The goal was to understand how the drug improves oxygen flow and quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI catch lung scarring that doctors might miss?
- Can a new pill ease the strain of pulmonary arterial hypertension?
- Could a gut bacteria transplant ease a rare lung disease?
- Can arm workouts boost oxygen use in lung disease?
- Can a diabetes drug help the heart burn fuel better in pulmonary hypertension?
- Can a smartwatch replace the clinic walk test for lung disease patients?